Under each agreement, Nightingale will analyze 10,000 UK Biobank samples using Alamar Biosciences’ NULISAseq Neuro 220 Panel, which measures proteins linked to neurodegeneration and other brain health conditions. The datasets will go to UK Biobank and be made available to the wider research community in 2027.

The aim is to find blood markers that change years before symptoms of diseases such as Alzheimer’s and Parkinson’s appear. That could help identify people at risk and support diagnostics and drug development. LifeArc’s focus includes rare dementias.

This agreement further expands what we believe to be the world’s largest brain health-focused proteomics study on a single research cohort.

The two deals expand a study Nightingale announced on September 30, when it signed a USD 6.5 million agreement to analyze 60,000 UK Biobank samples with the same panel.

“This agreement further expands what we believe to be the world’s largest brain health-focused proteomics study on a single research cohort,” says Teemu Suna, CEO and founder of Nightingale Health.